Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396442 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL345870 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL396425 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL394930 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL397047 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL6287445 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL392843 | 0.96 | LMNA (0.50) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL5943550 | 0.88 | LMNA (0.39) | LMNA | |
| SCHEMBL6283534 | 0.74 | — | — | |
| SCHEMBL1509092 | 0.74 | LMNA (0.35) | LMNACA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414716-A1 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS EMULSIONS | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | claimed |
| CN-116940347-A | Sustained release formulations emulsified using non-aqueous films | 里珍纳龙药品有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-4251128-A1 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS MEMBRANE EMULSIFICATION | Regeneron Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4065086-A1 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS EMULSIONS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-05 | — | — | EP | claimed |
| CN-114760986-A | Sustained release formulations using non-aqueous emulsions | 里珍纳龙药品有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022115588-A1 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS MEMBRANE EMULSIFICATION | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20050003977-A1 | Composition for cleaning | DAIKIN INDUSTRIES, LTD. (JP) | 2005-01-06 | — | — | US | claimed |
| EP-1447440-A1 | COMPOSITION FOR CLEANING | Daikin Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | claimed |
| EP-0091313-B1 | PERFLUOROHYDROCARBONS AS VEHICLES FOR ADMINISTERING DRUGS | ALCON LABORATORIES, INC. (US) | 1990-09-05 | — | — | EP | claimed |
| US-8871885-B2 | Ethylene-a-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8809462-B2 | Ethylene-α-olefin copolymer, molded article, catalyst for copolymerization, and method for producing an ethylene-α-olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140017687-A1 | METHOD FOR PERFORMING MOLECULAR REACTIONS BY USING IMMISCIBLE INTERMEDIATE FLUIDS | KONINKLIJKE PHILIPS N.V. (NL) | 2014-01-16 | — | — | US | disclosed |
| EP-1860141-B1 | Process for the surface modification of a polymer substrate and polymers formed therefrom | AMO UPPSALA AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501891-B2 | Ethylene-α-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| EP-0889067-A1 | Amorphous HFP/TFE copolymers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0808335-A2 | AMORPHOUS TETRAFLUOROETHYLENE-HEXAFLUOROPROPYLENE COPOLYMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5663255-A | POLYMERS FOR COATINGS, FILMS AND ENCAPSULATION WITH LOW COST POLYMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5637663-A | RADICAL INITIATING A CONTINUOUS COPOLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| WO-1996024624-A2 | AMORPHOUS TETRAFLUOROETHYLENE-HEXAFLUOROPROPYLENE COPOLYMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5478905-A | Reacting tetrafluoroethylene and hexafluoropropylene in the presence of a radical initiator | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414716-A1 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS EMULSIONS | FIBP, NPFFR1, VEGFA | LMNA 3871/4885CA1 3275/4885CA2 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.